The Food and Drug Administration is paying more attention to compounding pharmacies ever since the 2012 outbreak of fungal meningitis around the country. That epidemic was traced to contamination of a compound medication for injection made by the New England Compounding Center.
Today (April 2, 2015), the FDA has joined with the North Carolina Board of Pharmacy to urge health care professionals and patients to avoid any products made by the Prescription Center compounding pharmacy of Fayetteville, NC.
What Is the Problem?
The North Carolina Board of Pharmacy conducted an inspection of the facility in March and determined that there are serious concerns about the sterility, stability and potency of the medicines being compounded there. The Prescription Center has been closed and its products made between Sept. 10, 2014 and March 10, 2015 are being recalled.
How Should You Respond?
Human and veterinary prescribers are urged to check their drug supplies and quarantine any products that originated with the Prescribing Center.
Although this compounding pharmacy is located in North Carolina, it has been selling its products widely in North America. Any adverse effects that may be associated with Prescription Center products that have already been administered should be reported promptly to FDA’s MedWatch program.
